Trevicta (paliperidone palmitate) is a 3-monthly sustained-release injection for the maintenance treatment of schizophrenia. It can be given once patients are clinically stable on monthly paliperidone palmitate injection (Xeplion).
The extended dosing interval of Trevicta may help to reduce the risk of relapse caused by poor adherence to treatment.
Trevicta is administered by intramuscular injection into the deltoid or gluteal muscle, with dose adjustments when required within the range of 175mg to 525mg.
Similar to other antipsychotics, the most common adverse effects experienced by patients given the quarterly paliperidone palmitate injection included insomnia, extrapyramidal effects, weight change, hyperglycaemia, urinary tract infection, upper respiratory tract infection and headache.